(ERAS) Erasca - Ratings and Ratios
Naporafenib, ERAS-0015, ERAS-4001, ERAS-801, ERAS-601
ERAS EPS (Earnings per Share)
ERAS Revenue
Description: ERAS Erasca October 25, 2025
Erasca, Inc. (NASDAQ: ERAS) is a clinical-stage precision-oncology biotech that targets cancers driven by the RAS/MAPK signaling pathway. Its lead asset, naporafenib, is being evaluated in the SEACRAFT-2 pivotal Phase 3 trial for NRAS-mutated melanoma and in the SEACRAFT-1 Phase 1b study for NRAS Q61X melanoma. The company’s pipeline also includes a pan-RAS molecular glue (ERAS-0015), a pan-KRAS inhibitor (ERAS-4001), a biparatopic EGFR antibody (ERAS-12), a CNS-penetrant EGFR inhibitor for glioblastoma (ERAS-801), an oral ERK1/2 inhibitor (ERAS-007), and an oral SHP2 inhibitor (ERAS-601). Strategic licensing agreements with Novartis, Katmai Pharmaceuticals, and NiKang Therapeutics provide development, manufacturing, and commercialization rights for several of these candidates.
As of the most recent 10-Q, Erasca reported cash and cash equivalents of roughly $140 million, sufficient to fund operations into 2026 under current burn rates (~$30 million per year). The RAS-driven oncology market is projected to exceed $10 billion by 2030, driven by increasing prevalence of KRAS-mutant lung and colorectal cancers and a growing pipeline of targeted therapies. The company’s focus on molecular glues and pan-RAS inhibitors aligns with a sector-wide shift toward “undruggable” targets, a trend that has attracted >$5 billion of venture capital into RAS-focused biotech firms over the past 12 months.
Assuming successful Phase 3 read-out for naporafenib and continued enrollment in early-stage trials, Erasca could achieve a market-cap uplift of 30-50 % if it secures FDA approval and partners for commercialization. Conversely, any delay in trial timelines or adverse safety signals would materially increase dilution risk, given the company’s reliance on equity financing to extend its runway.
For a deeper quantitative comparison of ERAS against peers, the ValueRay platform offers a free analyst toolkit that can help you model scenario-based valuations.
ERAS Stock Overview
| Market Cap in USD | 655m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2021-07-16 |
ERAS Stock Ratings
| Growth Rating | -62.5% |
| Fundamental | 34.7% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -37.1% |
| Analyst Rating | 4.63 of 5 |
ERAS Dividends
Currently no dividends paidERAS Growth Ratios
| Growth Correlation 3m | 86.7% |
| Growth Correlation 12m | -23.2% |
| Growth Correlation 5y | -88.8% |
| CAGR 5y | -31.18% |
| CAGR/Max DD 3y (Calmar Ratio) | -0.36 |
| CAGR/Mean DD 3y (Pain Ratio) | -0.44 |
| Sharpe Ratio 12m | -0.05 |
| Alpha | -41.09 |
| Beta | 1.197 |
| Volatility | 72.33% |
| Current Volume | 1155.3k |
| Average Volume 20d | 1107.9k |
| Stop Loss | 2 (-9.1%) |
| Signal | 0.04 |
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income (-128.3m TTM) > 0 and > 6% of Revenue (6% = 251.8k TTM) |
| FCFTA -0.22 (>2.0%) and ΔFCFTA -1.02pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 6733 % (prev 7045 %; Δ -312.2pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.22 (>3.0%) and CFO -99.1m > Net Income -128.3m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 11.04 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (283.4m) change vs 12m ago 62.62% (target <= -2.0% for YES) |
| Gross Margin -8.41% (prev 28.66%; Δ -37.07pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 0.86% (prev 1.06%; Δ -0.20pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -5.80 (EBITDA TTM -145.0m / Interest Expense TTM 18.9m) >= 6 (WARN >= 3) |
Altman Z'' -15.39
| (A) 0.63 = (Total Current Assets 310.7m - Total Current Liabilities 28.2m) / Total Assets 445.4m |
| (B) -1.87 = Retained Earnings (Balance) -832.5m / Total Assets 445.4m |
| warn (B) unusual magnitude: -1.87 — check mapping/units |
| (C) -0.23 = EBIT TTM -109.4m / Avg Total Assets 485.6m |
| (D) -11.38 = Book Value of Equity -832.1m / Total Liabilities 73.1m |
| Total Rating: -15.39 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 34.68
| 1. Piotroski 0.0pt = -5.0 |
| 2. FCF Yield -24.55% = -5.0 |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.13 = 2.49 |
| 5. Debt/Ebitda 0.12 = 2.49 |
| 6. ROIC - WACC (= -31.08)% = -12.50 |
| 7. RoE -31.19% = -2.50 |
| 8. Rev. Trend 17.81% = 1.34 |
| 9. EPS Trend 67.17% = 3.36 |
What is the price of ERAS shares?
Over the past week, the price has changed by -6.78%, over one month by -5.58%, over three months by +46.67% and over the past year by -25.17%.
Is Erasca a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ERAS is around 1.77 USD . This means that ERAS is currently overvalued and has a potential downside of -19.55%.
Is ERAS a buy, sell or hold?
- Strong Buy: 5
- Buy: 3
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the ERAS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 4.5 | 104.5% |
| Analysts Target Price | 4.5 | 104.5% |
| ValueRay Target Price | 2 | -9.1% |
ERAS Fundamental Data Overview November 06, 2025
P/B = 1.6231
Beta = 1.197
Revenue TTM = 4.20m USD
EBIT TTM = -109.4m USD
EBITDA TTM = -145.0m USD
Long Term Debt = 49.4m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 4.71m USD (from shortTermDebt, last quarter)
Debt = 49.4m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -16.7m USD (from netDebt column, last quarter)
Enterprise Value = 404.0m USD (655.3m + Debt 49.4m - CCE 300.7m)
Interest Coverage Ratio = -5.80 (Ebit TTM -109.4m / Interest Expense TTM 18.9m)
FCF Yield = -24.55% (FCF TTM -99.2m / Enterprise Value 404.0m)
FCF Margin = -2364 % (FCF TTM -99.2m / Revenue TTM 4.20m)
Net Margin = -3057 % (Net Income TTM -128.3m / Revenue TTM 4.20m)
Gross Margin = -8.41% ((Revenue TTM 4.20m - Cost of Revenue TTM 4.55m) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 0.91 (Enterprise Value 404.0m / Total Assets 445.4m)
Interest Expense / Debt = 7.74% (Interest Expense 3.83m / Debt 49.4m)
Taxrate = 21.0% (US default 21%)
NOPAT = -86.4m (EBIT -109.4m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 11.04 (Total Current Assets 310.7m / Total Current Liabilities 28.2m)
Debt / Equity = 0.13 (Debt 49.4m / totalStockholderEquity, last quarter 372.3m)
Debt / EBITDA = 0.12 (negative EBITDA) (Net Debt -16.7m / EBITDA -145.0m)
Debt / FCF = 0.17 (negative FCF - burning cash) (Net Debt -16.7m / FCF TTM -99.2m)
Total Stockholder Equity = 411.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -28.80% (Net Income -128.3m / Total Assets 445.4m)
RoE = -31.19% (Net Income TTM -128.3m / Total Stockholder Equity 411.3m)
RoCE = -23.75% (EBIT -109.4m / Capital Employed (Equity 411.3m + L.T.Debt 49.4m))
RoIC = -21.01% (negative operating profit) (NOPAT -86.4m / Invested Capital 411.3m)
WACC = 10.07% (E(655.3m)/V(704.7m) * Re(10.37%) + D(49.4m)/V(704.7m) * Rd(7.74%) * (1-Tc(0.21)))
Discount Rate = 10.37% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 53.29%
Fair Price DCF = unknown (Cash Flow -99.2m)
EPS Correlation: 67.17 | EPS CAGR: 326.5% | SUE: 2.05 | # QB: 1
Revenue Correlation: 17.81 | Revenue CAGR: 0.0% | SUE: 0.0 | # QB: 0
Additional Sources for ERAS Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle